<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201305168146N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-06-02</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Siences</primary_sponsor>
      <public_title>Effect of 980 nm Diode laser lipolysis in submental area</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the efficacy and safety of the 980 nm Diode laser lipolysis and liposuction of submental area in shohada-Tajrish Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-06-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/8576</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Fat accumulation  in submental area.</hc_freetext>
      <i_freetext>Intervention 1: intervention group: patients with submental fat accumulation who undergot laser lipolysis&#13;
On the day of procedure, the area of target treatment is marked. Then patients are prep and draped in sterile fashion. Local tumescent anesthesia is composed of 1000 cc sodium chloride 0.9%, 100 cc lidocaine 1%, and 1cc epinephrine 1:1000.  A total tumescent of 200-300cc is delivered to the submental area. Upon delivery of tumescent, an incision of 1-3mm is created at the target treatment area for the introduction of cannula.  The 980nm diode laser (pharaon,OSYRIS, hellemmes,France) is used in continuous emission mode with power of 6-8 W. Laser energy is transmitted using a 600µm optical fiber encased in  a 1 mm diameter microcannula through the incision into the subcutaneous fat moving at the rate at least of 1cm/s. the microcannula is moved in a backward and forward fan-like motion in the horizontal plane to achieve homogenous distribution of the laser energy. The treated area is held by operator's hand to attenuate the resistance of tissue and manually measure the skin temperature. When laser energy delivery is complete, the liquefied fat was aspirated with a 3mm cannula. Intervention 2: control group(traditional liposuction)the patient’s neck is marked&#13;
with permanent marker to delineate the area to be treated, including the submental fat pad. The primary cannula entry point is located in the mental crease, approximately 0.5 cm directly posterior to the posterior border of the mandible at the chin. Liposuction is performed under sterile technique.&#13;
After being marked, the patient’s face, neck, and&#13;
chest is cleansed with chlorhexidine.  Local tumescent anesthesia is composed of 1000 cc sodium chloride 0.9%, 100 cc lidocaine 1%, and 1cc epinephrine 1:1000.  A total tumescent of 200-300cc is delivered to the submental area. The cannula is inserted into entry sites with the tip apertures facing downward, away from the dermis, to avoid inadvertent removal of superficial fat. Tunneling with the cannula is performed in linear, even strokes with the surgeon’s dominant hand, with the non dominant&#13;
hand, or “smart hand,” controlling cannula tip&#13;
position at all times. Multiple consecutive&#13;
passes are made in each tunnel with aspiration before moving to the next location.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Neda Valizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohada Tajrish Medical center, Tajrish Sq, Tehran,Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2274 9221</telephone>
        <email>barikbinb@yahoo.com</email>
        <affiliation>Laser application in medical research center,Shahid Beheshti University of medical sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behrooz Barikbin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohad Tajrish medical center,Tajrish Sq, Tehran,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2274 9221</telephone>
        <email>barikbinb@yahoo.com</email>
        <affiliation>IranLaser application in medical sciences research center,Shahid beheshti university of medical scie</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Female adults who express a desire for improving their submental contour were enrolled in this prospective randomized clinical trial.&#13;
Patients with any previous treatment such as liposuction or lipolysis or in submental region were excluded from the study. Subjects with infection in the area, bleeding tendency,weight variation of more than 10% in the follow up evaluation, known allergy to local anesthetics, history of compromised wound healing, pregnancy and pregnancy were exluded.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group: patients with submental fat accumulation who undergot laser lipolysis&#13;
On the day of procedure, the area of target treatment is marked. Then patients are prep and draped in sterile fashion. Local tumescent anesthesia is composed of 1000 cc sodium chloride 0.9%, 100 cc lidocaine 1%, and 1cc epinephrine 1:1000.  A total tumescent of 200-300cc is delivered to the submental area. Upon delivery of tumescent, an incision of 1-3mm is created at the target treatment area for the introduction of cannula.  The 980nm diode laser (pharaon,OSYRIS, hellemmes,France) is used in continuous emission mode with power of 6-8 W. Laser energy is transmitted using a 600µm optical fiber encased in  a 1 mm diameter microcannula through the incision into the subcutaneous fat moving at the rate at least of 1cm/s. the microcannula is moved in a backward and forward fan-like motion in the horizontal plane to achieve homogenous distribution of the laser energy. The treated area is held by operator's hand to attenuate the resistance of tissue and manually measure the skin temperature. When laser energy delivery is complete, the liquefied fat was aspirated with a 3mm cannula.</i_keyword>
      <i_keyword>control group(traditional liposuction)the patient’s neck is marked&#13;
with permanent marker to delineate the area to be treated, including the submental fat pad. The primary cannula entry point is located in the mental crease, approximately 0.5 cm directly posterior to the posterior border of the mandible at the chin. Liposuction is performed under sterile technique.&#13;
After being marked, the patient’s face, neck, and&#13;
chest is cleansed with chlorhexidine.  Local tumescent anesthesia is composed of 1000 cc sodium chloride 0.9%, 100 cc lidocaine 1%, and 1cc epinephrine 1:1000.  A total tumescent of 200-300cc is delivered to the submental area. The cannula is inserted into entry sites with the tip apertures facing downward, away from the dermis, to avoid inadvertent removal of superficial fat. Tunneling with the cannula is performed in linear, even strokes with the surgeon’s dominant hand, with the non dominant&#13;
hand, or “smart hand,” controlling cannula tip&#13;
position at all times. Multiple consecutive&#13;
passes are made in each tunnel with aspiration before moving to the next location.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fat reduction in patients. Timepoint: Before ,one week,one month, three months later. Method of measurement: Ultrasonography.</prim_outcome>
      <prim_outcome>Objective assessment. Timepoint: Before, one week, one month, three months later. Method of measurement: Picturing the patients and assessment by blinded physician.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Siences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-05-02</approval_date>
        <contact_name>Shahid Beheshti University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Daneshjoo Blvd., Velenjak st. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
